Display options
Cite
Afonin KA, Dobrovolskaia MA, Ke W, et al. Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation. Adv Drug Deliv Rev. 2021;114081doi: 10.1016/j.addr.2021.114081.
Afonin, K. A., Dobrovolskaia, M. A., Ke, W., Grodzinski, P., & Bathe, M. (2021). Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation. Advanced drug delivery reviews, 114081. https://doi.org/10.1016/j.addr.2021.114081
Afonin, Kirill A, et al. "Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation." Advanced drug delivery reviews vol. (2021): 114081. doi: https://doi.org/10.1016/j.addr.2021.114081
Afonin KA, Dobrovolskaia MA, Ke W, Grodzinski P, Bathe M. Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation. Adv Drug Deliv Rev. 2021 Dec 13;114081. doi: 10.1016/j.addr.2021.114081. Epub 2021 Dec 13. PMID: 34915069.
Copy Download .nbib Format: NLM
Share it on

Adv Drug Deliv Rev. 2021 Dec 13;114081. doi: 10.1016/j.addr.2021.114081. Epub 2021 Dec 13.

Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation.

Advanced drug delivery reviews

Kirill A Afonin, Marina A Dobrovolskaia, Weina Ke, Piotr Grodzinski, Mark Bathe

Affiliations

  1. Nanoscale Science Program, Department of Chemistry, The University of North Carolina at Charlotte, Charlotte, NC 28223, USA. Electronic address: [email protected].
  2. Nanotechnology Characterization Lab, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD 21702, USA.
  3. Biomedical Informatics and Data Science Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD 21702, USA.
  4. Nanodelivery Systems and Devices Branch, Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  5. Department of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA. Electronic address: [email protected].

PMID: 34915069 DOI: 10.1016/j.addr.2021.114081

Abstract

With numerous recent advances, the field of therapeutic nucleic acid nanotechnology is now poised for clinical translation supported by several examples of FDA-approved nucleic acid nanoformulations including two recent mRNA-based COVID-19 vaccines. Within this rapidly growing field, a new subclass of nucleic acid therapeutics called nucleic acid nanoparticles (NANPs) has emerged in recent years, which offers several unique properties distinguishing it from traditional therapeutic nucleic acids. Key unique aspects of NANPs include their well-defined 3D structure, their tunable multivalent architectures, and their ability to incorporate conditional activations of therapeutic targeting and release functions that enable diagnosis and therapy of cancer, regulation of blood coagulation disorders, as well as the development of novel vaccines, immunotherapies, and gene therapies. However, non-consolidated research developments of this highly interdisciplinary field provide crucial barriers that must be overcome in order to impact a broader range of clinical indications. Forming a consortium framework for nucleic acid nanotechnology would prioritize and consolidate translational efforts, offer several unifying solutions to expedite their transition from bench-to-bedside, and potentially decrease the socio-economic burden on patients for a range of conditions. Herein, we review the unique properties of NANPs in the context of therapeutic applications and discuss their associated translational challenges.

Copyright © 2021. Published by Elsevier B.V.

Keywords: dna origami; non-viral vector; nucleic acid nanotechnology; therapeutic nucleic acids; vaccine

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this pa

Publication Types

Grant support